Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis C transmission and prevention
US: Study finds little decline in hepatitis C infections among injection drug users

A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection.

Published
31 January 2011
From
EurekAlert!
Hepatitis C treatment
Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of the experimental hepatitis C protease inhibitor telaprevir. The agency has until May 23—six months from the original New Drug Application (NDA) filing date of November 23—to complete its review.

Published
21 January 2011
From
AIDSMeds
Hepatitis C treatment
Copy of Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of the experimental hepatitis C protease inhibitor telaprevir. The agency has until May 23—six months from the original New Drug Application (NDA) filing date of November 23—to complete its review.

Published
21 January 2011
From
Kaiser Daily Global Health Policy Report
Treatment-experienced people
Manufacturer Recalls Alcohol Swab Products Packaged with Fuzeon, Other Meds

The Triad Group alcohol prep pads, which may be contaminated with Bacillus cereus are co-packaged and distributed with some medications used by people living with HIV, including Genentech's Fuzeon (enfuvirtide) and Pegasys (pegylated interferon, used to treat chronic hepatitis C virus infection).

Published
20 January 2011
From
AIDSmeds
Hepatitis C symptoms and diagnosis
New drugs take aim at hepatitis C, spur debate on whether to test baby boomers

Surprisingly, two-thirds of hepatitis C sufferers are thought to be baby boomers who've harboured since their younger, perhaps wilder, years a virus that can take two or three decades to do its damage.

Published
18 January 2011
From
Canadian Press
Hepatitis C treatment
Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis C

Bristol Myers Squibb and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb’s NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset’s nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus (HCV).

Published
10 January 2011
From
Business Wire
Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C

Peregrine Pharmaceuticals announces open-label trial evaluating 12 weeks of therapy with novel targeted antibody bavituximab in combination with ribavirin versus standard of care.

Published
10 January 2011
From
Market Wire
Hepatitis C treatment
Merck Beats Vertex to FDA Hep C Filing

In the race to market the first next-generation treatment for hepatitis C, Merck is out to an early lead.

Published
07 January 2011
From
The Street
Hepatitis and HIV
Liver disease a possible predictor of stroke: Study

People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London health Sciences Centre. The study is the first to find a link between nonalcoholic fatty liver disease -- a disease characterized by the accumulation of fat in the liver in non drinkers -- and stroke.

Published
07 January 2011
From
Eurekalert Medicine & Health
Hepatitis C treatment
Pharmasset Reports Positive Results from its HCV Clinical Programs

Pharmasset, Inc. announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study. 

Published
06 January 2011
From
Pharmasset
← Prev1...150151152153154...155Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.